Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2 Trial to Investigate the Efficacy, Safety, and Tolerability of Efgartigimod PH20 SC in Adult Patients With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

Next Previous
Trial Profile

A Phase 2 Trial to Investigate the Efficacy, Safety, and Tolerability of Efgartigimod PH20 SC in Adult Patients With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 25 Jun 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Efgartigimod alfa (Primary) ; Hyaluronidase
  • Indications Chronic inflammatory demyelinating polyradiculoneuropathy
  • Focus Registrational; Therapeutic Use
  • Acronyms ADHERE
  • Sponsors argenx

Most Recent Events

  • 30 Dec 2025 According to an Halozyme Therapeutics media release, argenx VYVDURA (efgartigimod alfa and hyaluronidase-qvfc), has been granted regulatory approval by Japan's Ministry of Health, Labour and Welfare (MHLW) for adults with chronic inflammatory demyelinating polyneuropathy (CIDP) based on data from this study.
  • 20 Jun 2025 According to an argenx media release, company announced that the European Commission (EC) approved VYVGART (efgartigimod alfa) 1000mg for subcutaneous (SC) injection as a monotherapy for the treatment of adult patients with progressive or relapsing active chronic inflammatory demyelinating polyneuropathy (CIDP) after prior treatment with corticosteroids or immunoglobulins. The EC approval is based on positive results from the ADHERE clinical trial.
  • 28 Apr 2025 According to an Halozyme Therapeutics media release, company announced that argenx received a positive opinion from the CHMP of the European Medicines Agency recommending European Commission (EC) approval of efgartigimod alfa 1000mg developed with ENHANZE. The CHMP recommendation is based on positive results from the ADHERE clinical trial, The EC is expected to make a decision and the decision will apply to all 27 European Union Member States, and also to Iceland, Norway and Liechtenstein.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top